Succinate extended release
Pro Research Analysisby 
Searched over 200M research papers
Succinate Extended Release: Insights and Applications
Introduction to Metoprolol Succinate Extended Release
Metoprolol succinate extended release (ER) is a formulation designed to provide a controlled and consistent release of the drug over an extended period. This formulation is particularly beneficial for managing conditions such as hypertension and chronic heart failure, where maintaining stable drug levels is crucial for therapeutic efficacy.
Pharmacokinetics and Bioavailability
Consistent Drug Delivery
Metoprolol succinate ER tablets are engineered to deliver the drug at a near-constant rate for approximately 20 hours, independent of food intake and gastrointestinal pH. This results in even plasma concentrations over a 24-hour period, avoiding the peaks and troughs seen with immediate-release formulations . This consistent delivery ensures effective β1-blockade throughout the day, which is essential for managing heart failure and hypertension .
Bioequivalence Studies
Studies have shown that different formulations of metoprolol succinate ER tablets are bioequivalent under both fasting and fed conditions. This means that patients can expect similar therapeutic effects regardless of the specific brand or whether they take the medication with food .
Clinical Efficacy and Safety
Heart Failure Management
The MERIT-HF trial demonstrated that metoprolol succinate ER significantly reduces mortality and hospitalizations in patients with chronic heart failure. The trial showed a 34% reduction in all-cause mortality and a 19% reduction in the combined endpoint of mortality plus all-cause hospitalizations . These benefits were consistent across various patient subgroups, including the elderly and those with diabetes .
Hypertension in Children
In hypertensive children aged 6 to 16, metoprolol succinate ER has been shown to effectively lower blood pressure. The drug was well-tolerated, with no serious adverse events reported, making it a viable option for pediatric hypertension management .
Formulation Innovations
Multiple Unit Pellet Systems (MUPS)
Innovative formulations like the Multiple Unit Pellet System (MUPS) have been developed to enhance the extended-release profile of metoprolol succinate. MUPS formulations disintegrate into individual pellets after ingestion, providing a more controlled and prolonged drug release. This approach combines the benefits of single and multi-unit dosage forms, improving the drug's efficiency and stability .
Gastroretentive Floating Tablets
Another novel approach involves gastroretentive floating tablets, which are designed to increase stomach retention time and enhance drug bioavailability. These tablets use hydrophilic polymers and gas-producing agents to float in the stomach, ensuring a prolonged and consistent release of metoprolol succinate .
Economic Implications
The economic benefits of metoprolol succinate ER are significant. The MERIT-HF trial's economic analysis predicted substantial cost savings due to reduced hospitalizations and improved survival rates. This translates to a cost reduction of $395 to $1112 per patient over two years, highlighting the financial advantages of using this extended-release formulation in heart failure management .
Conclusion
Metoprolol succinate extended release offers a reliable and effective treatment option for managing hypertension and chronic heart failure. Its consistent drug delivery, proven clinical efficacy, and innovative formulations make it a valuable addition to therapeutic regimens. The economic benefits further underscore its importance in clinical practice, providing both health and financial advantages.
Sources and full results
Most relevant research papers on this topic
Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience.
Extended release metoprolol succinate is an effective and well-tolerated treatment for hypertension in children aged 6-16 years.
Pharmacokinetic Considerations of Formulation: Extended-Release Metoprolol Succinate in the Treatment of Heart Failure
Extended-release metoprolol succinate provides consistent and even -blockade over 24 hours, with good tolerability in heart failure patients.
Development and Evaluation of Novel Multi-unit Pellet System Formulation of Metoprolol Succinate for Extended Release
Multiple-unit pellet systems (MUPS) are ideal formulations for extended-release drugs like Metaprolol succinate, providing extended drug delivery and increased efficiency.
Formulation and Evaluation of Extended Release Gastroretentive Tablets of Metroprolol Succinate
The sustained-release floating tablets of Metoprolol succinate show potential as an alternative to conventional formulations, enhancing drug bioavailability and increasing stomach retention.
Formulation and In vitro Release Characterization of Metoprolol Succinate Extended Release Tablets
The optimal concentration of HPMC K100M (58%-65%) by direct compression method can yield an extended release of metoprolol succinate for 24 hours, meeting USP specifications.
DOI